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Abstract
Background—In December 2010, a case of West Nile virus (WNV) encephalitis occurring in a 
kidney recipient shortly after organ transplantation was identified.
Methods—A public health investigation was initiated to determine the likely route of 
transmission, detect potential WNV infections among recipients from the same organ donor, and 
remove any potentially infected blood products or tissues. Available serum, cerebrospinal fluid, 
and urine samples from the organ donor and recipients were tested for WNV infection by nucleic 
acid testing and serology.
Results—Two additional recipients from the same organ donor were identified, their clinical and 
exposure histories were reviewed, and samples were obtained. WNV RNA was retrospectively 
detected in the organ donor’s serum. After transplantation, the left kidney recipient had serologic 
and molecular evidence of WNV infection and the right kidney recipient had prolonged but 
clinically inapparent WNV viremia. The liver recipient showed no clinical signs of infection but 
had flavivirus IgG antibodies; however, insufficient samples were available to determine the 
timing of infection. No remaining infectious products or tissues were identified.
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Conclusions—Clinicians should suspect WNV as a cause of encephalitis in organ transplant 
recipients and report cases to public health departments for prompt investigation of the source of 
infection. Increased use of molecular testing and retaining pretransplantation sera may improve the 
ability to detect and diagnose transplant-associated WNV infection in organ transplant recipients.
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Since it was first detected in North America in 1999, West Nile virus (WNV) has become 
endemic to the continent and is responsible for focal seasonal outbreaks throughout the 
United States (1). Approximately 80% of human WNV infections are asymptomatic. Most 
symptomatic persons experience an acute systemic febrile illness; less than 1% of infected 
persons develop neuroinvasive disease, which typically manifests as meningitis, encephalitis, 
or acute flaccid paralysis (2–4). Although most WNV infections are acquired through the 
bite of an infected mosquito, the virus can also be transmitted through transfusion of 
infected blood products or solid-organ transplantation (SOT) (5–7).
WNV infection acquired through SOT can result in severe disease (8, 9). In five clusters of 
SOT-associated WNV infections previously reported to public health agencies in the United 
States, 10 of 13 (77%) organ recipients were infected (10, 11). Seven of the 10 (70%) 
infected organ recipients developed encephalitis and three of these patients died. SOT-
transmitted WNV infection is difficult to prevent because, unlike blood donors, organ donors 
are not routinely screened for WNV infection and, even with screening, some infections in 
donors may not be detected (5, 12).
In December 2010, a case of WNV encephalitis that occurred in a kidney recipient shortly 
after organ transplantation was identified. After recognition in this patient, a public health 
investigation was initiated to determine the likely route of transmission, detect any WNV 
infections among recipients from the same organ donor, and remove any potentially infected 
blood products or tissues. We report the findings of the investigation.
RESULTS
Three organs, a liver and two kidneys, were recovered from a single deceased donor and 
were transplanted into three recipients from northern California on the same day in October 
2010 (Table 1). No other organs or tissues from this donor were transplanted or stored. The 
liver recipient and left kidney recipient were transplanted at the same center, while the right 
kidney transplantation took place in another center.
Organ Donor
The organ donor was a 55-year-old male who had suffered blunt head trauma. He had a 
history of type 2 diabetes mellitus, hypertension, and drug use, and he had a coronary artery 
bypass graft in 2009. Routine organ donor screening showed evidence of prior 
cytomegalovirus and Epstein-Barr virus infection. The family reported that the donor had 
not had a recent history of a febrile illness and had no past history of meningitis or 
encephalitis. He had previously lived in Mexico for several years. Within 2 weeks before his 
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death, mosquitoes collected in his county of residence in California had tested positive for 
WNV. The donor was not screened for WNV infection before organ recovery; however, a 
retained serum specimen collected 3 days before organ procurement was retrospectively 
tested as part of this investigation and was positive for WNV RNA by individual 
(nonpooled) nucleic acid amplification testing (NAT). The sample also tested positive for 
WNV IgG but was negative for WNV IgM antibodies. Although he received one unit of 
packed red blood cells 2 days before organ recovery, the NAT-positive serum was collected 
before blood transfusion. Fixed brain, lung, thyroid, and heart tissue samples tested negative 
for WNV antigens.
Left Kidney Recipient
The left kidney recipient was a 73-year-old male with type 2 diabetes mellitus and end-stage 
renal disease. His medical history included cerebrovascular disease, chronic obstructive 
pulmonary disease, and prior heavy alcohol use. He was unsensitized, a zero human 
leukocyte antigen mismatch with his donor, and received basiliximab for induction therapy. 
Because of his age and history of diabetes, his maintenance regimen consisted of 
cyclosporine and mycophenolate mofetil (MMF). On posttransplantation day (PTD) 4, he 
received one unit of packed red blood cells. He was discharged home on PTD 6. He 
developed confusion on PTD 8, presented to another hospital emergency room on PTD 10, 
where his cyclosporine levels were markedly elevated and he was discharged home. He was 
rehospitalized at the transplant center on PTD 13 because of further deterioration of his 
mental status. At the time of readmission, he was hyponatremic (sodium 127 mmol/L) and 
had a possible infiltrate on chest radiograph. His symptoms were attributed to a combination 
of these findings. However, correction of his electrolytes, broad-spectrum antibiotics, and 
reduction of his cyclosporine dose did not yield improvement and further evaluation was 
performed to exclude other infectious etiologies. His mental status subsequently deteriorated 
rapidly, progressing to coma with limited brainstem reflexes and quadriplegia. An 
electroencephalogram showed diffuse slowing and a magnetic resonance imaging of the 
brain without contrast showed a chronic left posterior cerebellar artery infarct without other 
significant abnormalities. Electromyography and nerve conduction studies were normal. 
Cerebrospinal fluid (CSF) collected on PTD 18 revealed 32 white blood cells/mm3 (79% 
lymphocytes, 16% monocytes, and 5% neutrophils), two red blood cells/mm3, elevated 
protein (142 mg/dL), elevated glucose (105 mg/dL), negative bacterial culture, and negative 
cryptococcal antigen testing. During the third week of illness, samples were submitted to the 
California Encephalitis Project to test for viral etiologic agents of encephalitis, including 
WNV. Sera tested positive for WNV IgM and IgG antibodies that were confirmed by plaque 
reduction neutralization testing (PRNT). CSF collected on PTD 26 and 48 tested positive for 
WNV IgM antibodies, but no WNV RNA was detected. Retained pretransplantation serum 
collected 1 day before transplantation tested negative for WNV RNA and for both IgM and 
IgG antibodies. The patient’s immunosuppressive regimen was further reduced and 
ultimately withdrawn completely. He experienced transient improvement in responsiveness 
around PTD 67, but his condition subsequently declined and he died on PTD 113. An 
autopsy was conducted and postmortem brain tissues tested positive for WNV RNA.
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The patient had no known travel history, and there were no recent reports of WNV infections 
among humans or collected mosquitoes in his county of residence. The packed red blood 
cells that were received before his onset of encephalitis had tested negative for WNV during 
routine screening by minipool NAT at donation 5 weeks earlier. Follow-up testing of the 
blood donor at 114 days after the donation was negative for WNV RNA by individual 
(nonpooled) NAT, negative for WNV IgM antibodies, and positive for WNV IgG antibodies.
Right Kidney Recipient
The right kidney was transplanted into a 52-year-old female with polycystic kidney disease. 
Her medical history included migraine headaches and hypercoagulable state due to heparin-
induced thrombocytopenia. Her immunosuppressive regimen consisted of induction with 
rabbit antithymocyte globulin followed by maintenance with tacrolimus, MMF, and 
prednisone. Valganciclovir was given for cytomegalovirus prophylaxis. Despite 
postoperative slow graft function, no hemodialysis was required. To prevent acute antibody-
mediated injury, she received five plasmapheresis treatments from PTD 1 to 13 followed by 
120 g of intravenous immunoglobulin over PTD 16 to 19. She experienced gastrointestinal 
bleeding and received transfusions of several units of packed red blood cells and fresh frozen 
plasma on PTD 4 to 20. On PTD 16, she complained of headache and backache. Head 
computed tomography scan without contrast revealed no abnormality. The headache 
improved by PTD 19 with sumatriptan. Lumbar puncture was not performed. Kidney biopsy 
on PTD 20 demonstrated acute tubular necrosis with no evidence of acute rejection or C4d 
complement fragment deposition. She was discharged in stable condition on PTD 27. 
Arboviral testing on stored serum collected pretransplantation showed no evidence of WNV 
RNA or antibodies. After transplantation, she had evidence of WNV RNA by NAT on serum 
samples collected from PTD 96 to 103 and urine specimens collected from PTD 110 to 181. 
WNV IgM and IgG antibodies were detected on the earliest available posttransplantation 
serum sample collected on PTD 53. There was no immunohistochemical or molecular 
evidence of WNV infection on renal transplant tissue that was biopsied on PTD 20 and 178. 
The blood products that this patient received were not investigated further as a potential 
source of WNV infection because of the epidemiologic linkage to the WNV-positive organ 
donor and left kidney recipient as well as the effectiveness of blood donor screening. She 
remained in stable condition at more than 1 year after transplantation.
Liver Recipient
The liver was transplanted into a 47-year-old male with a history of chronic active hepatitis 
B virus infection resulting in liver cirrhosis and hepatocellular carcinoma. His exposure 
history was notable for extensive and frequent travel within the United States and to 
Southeast Asia. His postoperative course was uneventful and his immunosuppressive 
regimen consisted of MMF, tacrolimus, and prednisone; he remained on lamivudine and 
adefovir for the hepatitis B virus infection. On outpatient follow-up, he reported no 
symptoms suggestive of WNV infection after transplantation. Serum collected on PTD 52 
showed no detectable WNV RNA or IgM antibodies. WNV IgG antibodies were present but 
PRNT revealed fourfold greater neutralizing antibody titers against dengue viruses 
compared with WNV and St. Louis encephalitis virus. He remains in stable condition at 
more than 1 year after transplantation.
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This is the sixth cluster of confirmed SOT-transmitted WNV infections reported to public 
health agencies in the United States. Although the diagnosis of WNV encephalitis in the left 
kidney recipient was delayed until after 3 weeks of severe neuroinvasive disease, the ensuing 
public health investigation retrospectively confirmed organ donor viremia and excluded 
other routes of WNV transmission. Fortunately, no potentially infectious donor products or 
tissues remained that could have been transplanted in the interval between transplantation 
and the public health response.
Diagnosis of WNV in organ transplant recipients may be confounded by the initial 
attribution of symptoms to immunosuppressive drug toxicity or other infectious etiologies 
(14). Establishing the diagnosis of WNV infection in a transplant recipient may be 
challenging, as WNV viremia may be prolonged and antibody development may be delayed 
due to immunosuppressive medications (15, 16). This prolonged viremia and delayed 
antibody production was demonstrated in the right kidney recipient; however, her lack of 
severe symptoms is noteworthy and dissimilar to previous reports of prolonged symptomatic 
viremia in immunosuppressed patients (16). Overall, these findings suggest that molecular 
diagnostics may be of value for a longer time period after the initial infection and should be 
considered, in addition to antibody testing, to diagnose WNV infections in organ recipients.
The route of WNV transmission in recent organ recipients can only be deduced by 
establishing the timing of infection and investigating other possible exposures. To determine 
the timing and source of infection, paired sera collected immediately before and for several 
weeks after transplantation should be tested for WNV, and information on blood products 
administered and mosquito exposures should be obtained. The lack of archived 
pretransplantation recipient samples from recipients is a commonly cited limitation of 
donor-derived transmission investigations. Although donor sera are banked for 10 years by 
organ procurement organizations, sera and tissue biopsies from organ recipients before 
transplant are not routinely stored (17). In this investigation, the absence of 
pretransplantation serum from the liver recipient precluded a definitive determination of 
whether or not transplant-associated WNV infection had occurred. The presence of IgG 
antibodies and higher neutralizing titers against dengue in this recipient’s posttransplantation 
serum without detectable IgM antibodies suggests prior flavivirus infection. The prior 
flavivirus infection may have been acquired during travel to Asia or within the United States 
and might have conferred some protection against subsequent infection in this recipient (18–
20). In terms of alternate routes of transmission, public health WNV surveillance data did 
not support exposure to infected mosquitoes in the recipients’ counties of residence. One 
potential alternate source of WNV infection was investigated, namely, the packed red blood 
cells transfused to the left kidney recipient before symptom onset; however, this unit tested 
negative for WNV by minipool NAT at the time of donation. Furthermore, the blood donor 
of the unit was WNV IgM negative and IgG positive within 4months after donation. 
Although this does not definitively rule out recent WNV infection, the probability of IgM 
dropping to undetectable levels within that interval is low and the positive WNV IgG likely 
represents distant WNV infection in the blood donor (21). This, together with the 
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epidemiologic link of the organ donor and both kidney recipients, makes the blood 
transfusion an unlikely source of infection in the left kidney recipient.
Although proven effective treatment options for WNV disease remain elusive, clinicians 
caring for transplant recipients would benefit from early notification of possible SOT-
transmitted WNV infections to exclude other diagnoses, consider revision of 
immunosuppressive therapy, or contemplate use of investigational therapies such as 
polyclonal intravenous immunoglobulins in a transplant recipient with WNV infection (10, 
15, 22). It is unclear whether the immunoglobulin administered to the right kidney recipient 
in the early posttransplantation period to prevent acute antibody-mediated injury may have 
ameliorated the clinical course of WNV infection, especially because the patient failed to 
develop severe WNV disease despite a long period during which viral RNA was detectable 
in blood and urine.
During the investigation, retrospective WNV testing of stored serum from the organ donor 
demonstrated viremia 3 days before organ procurement, absence of IgM antibodies, and 
presence of IgG antibodies. The serologic findings may be attributable to prior non-WNV 
flavivirus infection with cross-reactive IgG antibodies but before developing an IgM 
antibody response to the acute WNV infection. WNV screening of organ donors is not a 
regulatory requirement and most organ procurement organizations have not employed 
systematic NAT-based screening for WNV among organ donors because of concerns that 
false-positive tests and prolonged turnaround times could compromise the availability of an 
already scarce supply of organs. In this case, the organ procurement organization did not 
perform routine WNV testing for these reasons as well as the low incidence of disease 
within their service area and the low level of reported WNV transmission nationally (23). 
Furthermore, because there have been prior reports of clusters in which organ donor viremia 
could not be detected, there is additional concern over the potential for missing cases by 
NAT testing (5, 12). Further prevention effectiveness evaluation is needed to determine if 
routine screening of organ donors results in a net benefit for transplant outcomes.
The conclusions drawn from this investigation are limited in two further aspects. First, the 
positive NAT on the donor serum, although replicated on repeat testing, was not confirmed 
by an alternative assay; second, the blood products transfused to the right kidney recipient 
were not investigated further as a potential source of infection.
Clinicians should have a high index of suspicion for WNV as a cause of systemic febrile 
illness or encephalitis in organ transplant recipients. Suspected cases should be reported to 
public health departments in a timely manner to enable a prompt investigation to identify 
and remove any potentially infected products and enable identification of other exposed 
recipients so they may be managed appropriately. Laboratory confirmation and 
determination of timing of WNV infection is dependent on appropriate testing, which could 
be improved by increased use of molecular methods in immunosuppressed patients, as well 
as banking of pretransplantation recipient sera. Furthermore, data from clusters of SOT-
transmitted WNV infections should be collected systematically, reported, and analyzed to 
inform future preventive efforts.
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We reviewed medical records and exposure history for the deceased-organ donor and 
obtained stored premortem sera as well as postmortem tissues for WNV testing. 
Investigators also searched for possible sources of the left kidney recipient’s WNV infection 
by reviewing his medical records and public health reports of local WNV activity (human 
and ecologic) in his county of residence. His stored sera and CSF collected before and after 
transplantation, respectively, were obtained for WNV testing to determine the timing of 
infection. Other recipients from the same deceased donor were identified and assessed for 
WNV infection by testing remaining pretransplantation samples and solicitation of 
posttransplantation samples as well as prospective clinical evaluation for signs of WNV 
disease. Finally, blood products that had been transfused into the left kidney recipient and 
organ donor were traced and investigated.
Laboratory Testing
Serum, CSF, and urine samples were tested for WNV at the California Department of Public 
Health, the Centers for Disease Control and Prevention, and commercial laboratories. Sera 
were tested for WNV RNA by reverse transcription-polymerase chain reaction (24). Organ 
donor sera also were tested for WNV RNA by NAT using the Gen-Probe Procleix assay, 
which uses a larger input sample volume for testing to increase sensitivity (25). All serum 
and CSF samples were tested for WNV-specific IgM and IgG antibodies by enzyme-linked 
immunosorbent assay or microsphere-based immunoassay (26, 27). Antibody specificity for 
WNV was confirmed by PRNT (28). Tissue samples were tested for WNV RNA by reverse 
transcription-polymerase chain reaction and for WNV and pan-flavivirus antigens by 
immunohistochemistry (24, 29).
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